Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Maze Therapeutics, Inc. ( (MAZE) ).
On April 21, 2026, Maze Therapeutics, Inc. priced an underwritten registered offering of 5,540,000 shares of common stock at $23.50 per share and pre-funded warrants for 850,000 shares at $23.499, for expected gross proceeds of $150 million and estimated net proceeds of about $144.7 million. The deal, underwritten solely by Leerink Partners and expected to close around April 23, 2026, drew participation from a mix of new and existing specialist healthcare and institutional investors.
Maze plans to use the proceeds primarily to advance clinical development of its lead candidates MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, as well as for general corporate purposes. The capital raise, combined with existing cash and marketable securities, is expected to fund the company’s operations into 2029, extending its cash runway and supporting its position in the competitive kidney and metabolic disease therapeutics market.
The most recent analyst rating on (MAZE) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Maze Therapeutics, Inc. stock, see the MAZE Stock Forecast page.
Spark’s Take on MAZE Stock
According to Spark, TipRanks’ AI Analyst, MAZE is a Neutral.
The score is held down primarily by volatile fundamentals (sharp swing from profitable 2024 to zero-revenue, high-loss, cash-burning 2025) and weak technical momentum (below key moving averages with negative MACD). Offsetting factors include constructive corporate developments (positive Phase 2 data, milestone payment, and improved liquidity options), but valuation support is limited given losses and no dividend.
To see Spark’s full report on MAZE stock, click here.
More about Maze Therapeutics, Inc.
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule precision medicines for kidney and metabolic diseases, guided by its human genetics-based Compass platform. Its pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease, and MZE782, an SLC6A19 inhibitor advancing to Phase 2 for phenylketonuria and chronic kidney disease, with headquarters in South San Francisco.
The company focuses on genetically validated targets and aims to advance first- or best-in-class programs for patients with serious renal and metabolic conditions. By leveraging variant discovery and functionalization, Maze seeks to translate human genetic insights into therapeutics, positioning itself within the precision medicine segment of the biopharma industry.
Average Trading Volume: 841,518
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.33B
See more insights into MAZE stock on TipRanks’ Stock Analysis page.